You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. A device containing an immobilized chelator to remove aluminum from total parente

    SBC: ALKYMOS, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. An Advanced Biosensor for Molecular Interaction Studies

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates

    SBC: APOIMMUNE, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Commercialization of a Diagnostic Test for Alzheimer's Disease

    SBC: SCOUT DIAGNOSTICS            Topic: NIA

    DESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stages when therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this project is that levels of a unique high mo ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Fluorescence Intensity-Based Scoring of Macromolecule Crystallization Plates

    SBC: iXpressGenes, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Crystallization, followed by subsequent structure determination, is a major step in understanding the structure-function relationship of macromolecules. Understanding macromolecule structure has become a key part in the development of new pharmaceuticals, and is a major area of NIH research. Crystallization however is also the rate limiting step, despite techn ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Intranasal Naloxone: An Opioid Overdose Antidote

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered pharmaceutical - naloxone (NLX) hydrochloride - for the emergency treatment of opioid overdose by emerge ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Islet Protection from Hypoxia Posttransplant

    SBC: BIOINVENTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Islet transplantation (ITx), especially with the emerging potential of xenotransplantation, holds significant promise for the treatment of type 1 diabetes (T1D). There are, however, major challenges that remain prior to its larger scale, cost-effective application. Hypoxia is a leading stress post-transplantation and is estimated to cause the death of approxima ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Novel estrogen receptor ligands from plant genomics

    SBC: NAPROGENIX, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Human nuclear receptor (HNR) ligands have potential value as pharmacotherapies or chemopreventive agents for many hormone-responsive cancers. The primary aim of this STTR is to transfer an academic plant genomics technology into drug discovery, targeting HNR ligands. Estrogen receptor (ER) ligands in plants will be used for proof of application, because these ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Methods for Dissolving Blood Clots

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of death worldwide. Current therapies for cardiovascular disease are associated with partial success, restricted access, delays, possible neurotoxicity and other important limitations. Our goal is to develop a novel therapeutic agent that is safer and more effective at dissolving the blood clots (thrombi) that cause h ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government